Virogin Biotech

Exciting news from Virogin Biotech! We're thrilled to announce that our promising clinical trial data for VG161 in advanced HCC has been selected for a poster presentation at ASCO 2024. https://lnkd.in/gzJgCjvH Please visit us at Poster Board: 85, Session Time: 1:30 PM - 4:30 PM, June 1, 2024. Our latest results will showcase significant survival benefits for patients with advanced Hepatocellular Carcinoma with no treatment options.    Details of the poster presentation:    Title: Clinical outcomes from a phase I trial of the novel oncolytic virus VG161 in patients with hepatocellular carcinoma refractory after two prior lines of therapy including checkpoint inhibitors.  Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary  Abstract Number: 4105  Poster Board: 85  Session Time: 1:30 PM - 4:30 PM, June 1, 2024    These advances underscore our commitment to pioneering cancer therapies that truly make a difference.    #ASCO2024 #Cancer #Oncology #HCC #Hepatocellular Carcinoma #OncolyticVirus #ViroginBiotech 

Exciting news from Virogin Biotech! We're thrilled to announce that our promising clinical trial data for VG161 in advanced HCC has been selected for a poster presentation at ASCO 2024. https://lnkd.in/gzJgCjvH Please visit us at Poster Board: 85, Session Time: 1:30 PM - 4:30 PM, June 1, 2024. Our latest results will showcase significant survival benefits for patients with advanced Hepatocellular Carcinoma with no treatment options.    Details of the poster presentation:    Title: Clinical outcomes from a phase I trial of the novel oncolytic virus VG161 in patients with hepatocellular carcinoma refractory after two prior lines of therapy including checkpoint inhibitors.  Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary  Abstract Number: 4105  Poster Board: 85  Session Time: 1:30 PM - 4:30 PM, June 1, 2024    These advances underscore our commitment to pioneering cancer therapies that truly make a difference.    #ASCO2024 #Cancer #Oncology #HCC #Hepatocellular Carcinoma #OncolyticVirus #ViroginBiotech 

We're excited to share that our CSO & Co-Founder, Dr. William Jia, will be speaking at the 3rd Annual Next Generation RNA Therapeutics Summit, happening from May 7-9, 2024, in Boston, MA. He will present on the topic "A Novel saRNA Backbone for Reduced Cytotoxicity & Enhanced Payload Expression" at 12:30 PM on May 8, 2024. Join us to explore the latest advancements in Self- Amplifying RNA Therapeutics and learn how Virogin Biotech is pioneering novel saRNA platform for enhanced patient outcomes. With 30 years of expertise in virology and immunology, we're developing the saRNA platform as the next-gen technology. Check out the event agenda here: https://ter.li/zueqed #RNATherapeutics #RNAInnovation #NextGenRNA2024 #ViroginBiotech

Check out the latest report from IMIR Market Research™ on the 𝗢𝗻𝗰𝗼𝗹𝘆𝘁𝗶𝗰 𝗩𝗶𝗿𝘂𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Oncolytic Virus Therapy Market Size, Share & Trends Analysis Report By Virus Type Outlook (Revenue, USD Million; 2018–2028) (Genetically Engineered Oncolytic Viruses {Herpes Simplex Virus, Adenovirus, Vaccinia Virus}, Oncolytic Wild-Type Viruses {Reovirus, Newcastle Disease Virus, Vesicular Stomatitis Virus}), By Application Outlook (Revenue, USD Million; 2018–2028) (Solid Tumors {Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma}), Melanoma {Hematological Malignancies, Lymphoma, Leukemia, Myeloma}), By End-use Outlook (Revenue, USD Million; 2018–2028) (Hospitals, Specialty Clinics, Cancer Research Institute), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/dpJ6dfmE 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 Turnstone Biologics ABL Inc. Sorrento Therapeutics, Inc. Vibalogics Matica Biotechnology, Inc. LumaCyte NecstGen Theriva Biologics, Inc. Virogin Biotech Able IconOVir Bio VYROBIO Eurofins Viracor BioPharma Services Redbiotec AG Genelux OBiO Tech KaliVir Immunotherapeutics Forecyte Bio Limited ImmVirX GeneMedicine ViraTherapeutics GmbH RES Group, Inc Amgen DNAtrix Genelux Lokon Pharma AB Replimune  Rigvir Sorrento Therapeutics, Inc. Takara Bio USA, Inc. Targovax TILT Biotherapeutics Ltd Transgene SA (TGNA) Vyriad. Oncolytics Biotech Inc. Daiichi Sankyo US  Shanghai Sunway Biotech Co. Ltd. Takara Bio USA, Inc..

Virogin Biotech announced its publication detailing a new generation mRNA therapeutic vaccine for HPV-related tumors in Immunology. Through selective targeting and activation of antigen-presenting cells, our self-adjuvant vaccine M22H04 achieves efficient activation of anti-tumor immunity, leading to complete tumor regression and prevented tumor recurrence. Our vaccine encodes two modified oncoproteins, E6 and E7, fused with an antigen-presenting cell (APC)-targeting immunogen within the LNP-encapsulated mRNA vaccine. For more details, you can read the full article on Virogin's website here: https://lnkd.in/dsJ6wvMu   The study emphasizes the effectiveness of mRNA technology in cancer vaccine development over traditional vaccines. Virogin’s research in mRNA therapeutic vaccines underscores its capability to develop potent vaccines and highlights how its deep understanding of immunology contributes to pioneering vaccine approaches.   #HPV #CancerVaccine #mRNATherapeuticVaccine #Immunotherapy #mRNA #Vaccines #Women’sHealth

Virogin Biotech proudly showcased our pioneering research at the 3rd mRNA-Based Therapeutics Summit Europe in Berlin, the premier gathering for mRNA professionals. Our CSO, Dr. William Jia, presented our findings in a poster titled "Oncolytic Virotherapy: Overcoming Hurdles in the Realm of mRNA Vaccines," now available on Virogin's website here: https://lnkd.in/gnNMFu-A Our research addresses the significant challenges faced by mRNA vaccines, including the immune-suppressive tumor microenvironment (TME) and more importantly, the resistance induced by antigen-specific tumor vaccine. Oncolytic virotherapy (OV) emerges as a game-changer, enhancing the immune response by altering the tumor microenvironment and broadening the spectrum of tumor antigens via tumor cell lysis to overcome the heterogeneity of solid tumors #mRNA #cancervaccines #Immunotherapy #OncolyticViruses #HER2 #Vaccines #PrimeBoost #mRNAtherapeuticssummit

Virogin Biotech has published a pathbreaking study detailing their homologous prime boost strategy in Vaccines, demonstrating that combination of HER2-expressing oHSV-1 followed by intratumoral oHSV-1 not only triggers robust immune responses against HER2+ tumor cells but also induces tumor antigen spread with enhanced systemic anti-tumor efficacy targeting a much broader antigen spectrum. For more details, you can read the full article on Virogin's website here: https://lnkd.in/gW-wQTMB Virogin is also working on the combination of oncolytic virus with other tumor vaccines such as mRNA cancer vaccines. A publication is in preparation, please stay tuned.   #CancerResearch #Immunotherapy #OncolyticViruses #HER2 #Vaccines #CancerVaccines #PrimeBoost

Virogin Biotech has published a pathbreaking study detailing their homologous prime boost strategy in Vaccines, demonstrating that combination of HER2-expressing oHSV-1 followed by intratumoral oHSV-1 not only triggers robust immune responses against HER2+ tumor cells but also induces tumor antigen spread with enhanced systemic anti-tumor efficacy targeting a much broader antigen spectrum. For more details, you can read the full article on Virogin's website here: https://lnkd.in/gW-wQTMB Virogin is also working on the combination of oncolytic virus with other tumor vaccines such as mRNA cancer vaccines. A publication is in preparation, please stay tuned.   #CancerResearch #Immunotherapy #OncolyticViruses #HER2 #Vaccines #CancerVaccines #PrimeBoost

Virogin Biotech has published a groundbreaking study detailing their novel Monkeypox mRNA vaccine in Nature Communications, a prestigious peer-reviewed journal widely recognized by the scientific community. For more details, you can read the full article on Virogin's website here: https://lnkd.in/dpX_YaQS Our vaccine uniquely fuses two monkeypox antigens into a single mRNA sequence, demonstrating a significantly enhanced immune response compared to traditional methods. This approach resulted in effective protection against vaccinia virus infection in mice within just seven days post-vaccination. The success in developing the novel mRNA vaccine against monkeypox showcased Virogin’s capability of prompt response to an emerging pathogen and how its in-depth understanding in immunology benefits the development of vaccines against more complex pathogens. The publication further solidifies Virogin’s contribution to the scientific community and potential impact on global health. #MonkeypoxVaccine #mRNAVaccine #NatureCommunications #VacciniaVirus #GlobalHealth #VaccineDevelopment #EmergingPathogens